Tripeptidyl-peptidase II controls DNA damage responses and in vivo γ-irradiation resistance of tumors

Cancer Research

Volumn 67, Issue 15, 2007, Pages 7165-7174

  Hong, Xu ^a   Lei, Lu ^a   Künert, Brita ^a   Naredla, Rajender ^a   Applequist, Steven E ^a   Grandien, Alf ^a   Glas, Rickard ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

PEPTIDASE; PHOSPHATIDYLINOSITOL 3 KINASE; RAPAMYCIN; TRIPEPTIDYL PEPTIDASE II; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER RESISTANCE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DNA DAMAGE; DRUG TARGETING; GAMMA IRRADIATION; GAMMA RADIATION; HUMAN; HUMAN CELL; IN VIVO STUDY; INHIBITION KINETICS; LYMPHOMA; LYMPHOMA CELL; MOLECULAR DYNAMICS; MOLECULAR WEIGHT; NONHUMAN; PRIORITY JOURNAL; PROTEIN STABILITY; PROTEIN TARGETING; RADIATION DOSE; RADIATION EXPOSURE; RADIOSENSITIVITY; REGULATORY MECHANISM; TUMOR GROWTH; TUMOR REGRESSION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; AMINO ACID SEQUENCE; ANIMALS; DNA DAMAGE; ENZYME INHIBITORS; FLOW CYTOMETRY; GAMMA RAYS; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPHOMA; MICE; MICE, INBRED C57BL; MOLECULAR SEQUENCE DATA; PLASMIDS; PROTEIN-SERINE-THREONINE KINASES; RADIATION TOLERANCE; RNA, SMALL INTERFERING; SERINE ENDOPEPTIDASES; SIGNAL TRANSDUCTION; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 34547613351     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-4094     Document Type: Article

References (50)

1. Brown JM, Attardi LD. The role of apoptosis in cancer development and treatment response. Nat Rev Cancer 2005;5:231-7.
2. Yonekura I, Takai K, Asai A, Kawahara N, Kirino T. p53 potentiates hippocampal neuronal death caused by global ischemia. J Cereb Blood Flow Metab 2006;26:1332-40.
3. Lau A, Swinbank KM, Ahmed PS, et al. Suppression of HIV-1 infection by a small molecule inhibitor of the ATM kinase. Nat Cell Biol 2005;7:493-500.
4. Bakkenist CJ, Kastan MB. Initiating cellular stress responses. Cell 2004;118:9-17.
5. McKinnon PJ. ATM and ataxia telangiectasia. EMBO Rep 2004;5:772-6.
6. Bartkova J, Horejsi Z, Koed K, et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 2005;434:907-13.
7. Bartkova J, Horejsi Z, Koed K, et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 2005;434:864-70.
8. Barlow C, Hirotsune S, Paylor R, et al. Atm-deficient mice: a paradigm of ataxia telangiectasia. Cell 1996;86:159-71.
9. Cowell IG, Durkacz BW, Tilby MJ. Sensitization of breast carcinoma cells to ionizing radiation by small molecule inhibitors of DNA-dependent protein kinase and ataxia telangiectasia mutated. Biochem Pharmacol 2005;71:13-20.
10. Choi EK, Ji IM, Lee SR, et al. Radiosensitization of tumor cells by modulation of ATM kinase. Int J Radiat Biol 2006;82:277-83.
11. Zhao Y, Thomas HD, Batey MA, et al. Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441. Cancer Res 2006;66:5354-62.
12. Faivre S, Kroemer G, Raymond E. Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov 2006;5:671-88.
13. Eshleman JS, Carlson BL, Mladek AC, Kastner BD, Shide KL, Sarkaria JN. Inhibition of the mammalian target of rapamycin sensitizes U87 xenografts to fractionated radiation therapy. Cancer Res 2002;62:7291-7.
14. Weppler SA, Krause M, Zyromska A, Lambin P, Baumann M, Wouters BG. Response of U87 glioma xenografts treated with concurrent rapamycin and fractionated radiotherapy: possible role for thrombosis. Radiother Oncol 2007;82:96-104.
15. Tirado OM, Mateo-Lozano S, Sanders S, Dettin LE, Notario V. The PCPH oncoprotein antagonizes the proapoptotic role of the mammalian target of rapamycin in the response of normal fibroblasts to ionizing radiation. Cancer Res 2003;63:6290-8.
16. Bao S, Wu Q, McLendon RE, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006;444:756-60.
17. Reinhardt HC, Aslanian AS, Lees JA, Yaffe MB. p53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage. Cancer Cell 2007;11:175-89.
18. Glas R, Bogyo M, McMaster JS, Gaczynska M, Ploegh HL. A proteolytic system that compensates for loss of proteasome function. Nature 1998;392:618-22.
19. Geier E, Pfeifer G, Wilm M, et al. A giant protease with potential to substitute for some functions of the proteasome. Science 1999;283:978-81.
20. Gavioli R, Frisan T, Vertuani S, Bornkamm GW, Masucci MG. c-myc overexpression activates alternative pathways for intracellular proteolysis in lymphoma cells. Nat Cell Biol 2001;3:283-8.
21. Hong X, Lei L, Glas R. Tumors acquire inhibitor of apoptosis protein (IAP)-mediated apoptosis resistance through altered specificity of cytosolic proteolysis. J Exp Med 2003;197:1731-43.
22. Tomkinson B, Lindas AC. Tripeptidyl-peptidase II: a multi-purpose peptidase. Int J Biochem Cell Biol 2005;37:1933-7.
23. Renn SC, Tomkinson B, Taghert PH. Characterization and cloning of tripeptidyl peptidase II from the fruit fly, Drosophila melanogaster. J Biol Chem 1998;273:19173-82.
24. Rockel B, Peters J, Kuhlmorgen B, Glaeser RM, Baumeister W. A giant protease with a twist: the TPPII complex from Drosophila studied by electron microscopy. EMBO J 2002;21:5979-84.
25. Reits E, Neijssen J, Herberts C, et al. A major role for TPPII in trimming proteasomal degradation products for MHC class I antigen presentation. Immunity 2004;20:495-506.
26. York IA, Bhutani N, Zendzian S, Goldberg AL, Rock KL. Tripeptidyl peptidase II is the major peptidase needed to trim long antigenic precursors, but is not required for most MHC class I antigen presentation. J Immunol 2006;177:1434-43.
27. Hilbi H, Puro RJ, Zychlinsky A. Tripeptidyl peptidase II promotes maturation of caspase-1 in Shigella flexneri-induced macrophage apoptosis. Infect Immun 2000;68:5502-8.
28. Stavropoulou V, Xie J, Henriksson M, Tomkinson B, Imreh S, Masucci MG. Mitotic infidelity and centrosome duplication errors in cells overexpressing tripeptidyl-peptidase II. Cancer Res 2005;65:1361-8.
29. Stavropoulou V, Vasquez V, Cereser B, Freda E, Masucci MG. TPPII promotes genetic instability by allowing the escape from apoptosis of cells with activated mitotic checkpoints. Biochem Biophys Res Commun 2006;346:415-25.
30. Brummelkamp TR, Bernards R, Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science 2002;296:550-3.
31. Tomkinson B, Wernstedt C, Hellman U, Zetterqvist O. Active site of tripeptidyl peptidase II from human erythrocytes is of the subtilisin type. Proc Natl Acad Sci USA 1987;84:7508-12.
32. Wang EW, Kessler BM, Borodovsky A, et al. Integration of the ubiquitin-proteasome pathway with a cytosolic oligopeptidase activity. Proc Natl Acad Sci U SA 2000;97:9990-5.
33. Rose C, Vargas F, Facchinetti P, et al. Characterization and inhibition of a cholecystokinin-inactivating serine peptidase. Nature 1996;380:403-9.
34. Bork P, Hofmann K, Bucher P, Neuwald AF, Altschul SF, Koonin EV. A superfamily of conserved domains in DNA damage-responsive cell cycle checkpoint proteins. FASEB J 1997;11:68-76.
35. Manke IA, Lowery DM, Nguyen A, Yaffe MB. BRCT repeats as phosphopeptide-binding modules involved in protein targeting. Science 2003;302:636-9.
36. Yu X, Chini CC, He M, Mer G, Chen J. The BRCT domain is a phospho-protein binding domain. Science 2003;302:639-42.
37. Viniegra JG, Martinez N, Modirassari P, et al. Full activation of PKB/Akt in response to insulin or ionizing radiation is mediated through ATM. J Biol Chem 2005;280:4029-36.
38. Feng J, Park J, Cron P, Hess D, Hemmings BA. Identification of a PKB/Akt hydrophobic motif Ser-473 kinase as DNA-dependent protein kinase. J Biol Chem 2004;279:41189-96.
39. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005;307:1098-101.
40. Dan HC, Sun M, Kaneko S, et al. Akt phosphorylation and stabilization of X-linked inhibitor of apoptosis protein (XIAP). J Biol Chem 2004;279:5405-12.
41. Gasser S, Orsulic S, Brown EJ, Raulet DH. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature 2005;436:1186-90.
42. Choudhury A, Cuddihy A, Bristow RG. Radiation and new molecular agents part I: targeting ATM-ATR checkpoints, DNA repair, and the proteasome. Semin Radiat Oncol 2006;16:51-8.
43. Munger K, Duensing S. Methods of use for tripeptidyl-peptidase II inhibitors as anticancer agents. International/Publication number WO 03/105835 A1. Dec. 2003.
44. Dantuma NP, Lindsten K, Glas R, Jellne M, Masucci MG. Short-lived green fluorescent proteins for quantifying ubiquitin/proteasome-dependent proteolysis in living cells. Nat Biotechnol 2000;18:538-43.
45. El-Deiry WS. The role of p53 in chemosensitivity and radiosensitivity. Oncogene 2003;22:7486-95.
46. Bode AM, Dong Z. Post-translational modification of p53 in tumorigenesis. Nat Rev Cancer 2004;4:793-805.
47. Shinohara ET, Cao C, Niermann K, et al. Enhanced radiation damage of tumor vasculature by mTOR inhibitors. Oncogene 2005;24:5414-22.
48. Boehm T, Folkman J, Browder T, O'Reilly MS. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997;390:404-7.
49. Zhang S, Hemmerich P, Grosse F. Centrosomal localization of DNA damage checkpoint proteins. J Cell Biochem 2006;101:451-65.
50. De Winter H, Breslin H, Miskowski T, Kavash R, Somers M. Inhibitor-based validation of a homology model of the active-site of tripeptidyl peptidase II. J Mol Graph Model 2005;23:409-18.